DK3523283T3 - Crystalline and salt forms of ppar agonist compounds - Google Patents
Crystalline and salt forms of ppar agonist compounds Download PDFInfo
- Publication number
- DK3523283T3 DK3523283T3 DK17787774.3T DK17787774T DK3523283T3 DK 3523283 T3 DK3523283 T3 DK 3523283T3 DK 17787774 T DK17787774 T DK 17787774T DK 3523283 T3 DK3523283 T3 DK 3523283T3
- Authority
- DK
- Denmark
- Prior art keywords
- crystalline
- salt forms
- agonist compounds
- ppar agonist
- ppar
- Prior art date
Links
- 101150014691 PPARA gene Proteins 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 150000003839 salts Chemical group 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662404474P | 2016-10-05 | 2016-10-05 | |
| PCT/US2017/055403 WO2018067860A1 (en) | 2016-10-05 | 2017-10-05 | Crystalline and salt forms of ppar agonist compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3523283T3 true DK3523283T3 (en) | 2021-06-28 |
Family
ID=60153508
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17787774.3T DK3523283T3 (en) | 2016-10-05 | 2017-10-05 | Crystalline and salt forms of ppar agonist compounds |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US10927094B2 (https=) |
| EP (1) | EP3523283B1 (https=) |
| JP (1) | JP7017563B2 (https=) |
| KR (1) | KR20190057129A (https=) |
| CN (1) | CN109843857B (https=) |
| AU (1) | AU2017340763B2 (https=) |
| CA (1) | CA3036587A1 (https=) |
| CO (1) | CO2019003162A2 (https=) |
| CY (1) | CY1124655T1 (https=) |
| DK (1) | DK3523283T3 (https=) |
| ES (1) | ES2887008T3 (https=) |
| HR (1) | HRP20211341T1 (https=) |
| HU (1) | HUE055678T2 (https=) |
| IL (1) | IL265730B (https=) |
| JO (1) | JOP20190039B1 (https=) |
| LT (1) | LT3523283T (https=) |
| MA (1) | MA46460A (https=) |
| MX (1) | MX385973B (https=) |
| MY (1) | MY202008A (https=) |
| PH (1) | PH12019500727A1 (https=) |
| PL (1) | PL3523283T3 (https=) |
| PT (1) | PT3523283T (https=) |
| RS (1) | RS62245B1 (https=) |
| RU (1) | RU2759724C2 (https=) |
| SG (1) | SG11201901995TA (https=) |
| SI (1) | SI3523283T1 (https=) |
| TW (1) | TWI769182B (https=) |
| UA (1) | UA124770C2 (https=) |
| WO (1) | WO2018067860A1 (https=) |
| ZA (1) | ZA201901744B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006249866B2 (en) | 2005-05-26 | 2011-10-13 | Aldeyra Therapeutics, Inc. | Compositions and methods of treating retinal disease |
| WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| CN117045653A (zh) | 2013-01-23 | 2023-11-14 | 奥尔德拉医疗公司 | 与毒性醛相关的疾病和治疗 |
| US10550085B2 (en) | 2015-08-21 | 2020-02-04 | Aldeyra Therapeutics, Inc. | Deuterated compounds and uses thereof |
| EA037371B1 (ru) * | 2015-10-07 | 2021-03-19 | Митобридж, Инк. | Агонисты ppar, соединения, фармацевтические композиции и способы их применения |
| ES2887008T3 (es) | 2016-10-05 | 2021-12-21 | Mitobridge Inc | Formas cristalinas y de sal de compuestos agonistas del PPAR |
| WO2019075136A1 (en) | 2017-10-10 | 2019-04-18 | Aldeyra Therapeutics, Inc. | TREATMENT OF INFLAMMATORY DISORDERS |
| AU2019319740A1 (en) * | 2018-08-06 | 2021-03-25 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| WO2020085393A1 (ja) | 2018-10-23 | 2020-04-30 | 国立研究開発法人科学技術振興機構 | ＰＰＡＲδ活性化剤 |
| JP2022530967A (ja) | 2019-05-02 | 2022-07-05 | アルデイラ セラピューティクス， インコーポレイテッド | 多形化合物およびその使用 |
| WO2020223717A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| WO2021231792A1 (en) | 2020-05-13 | 2021-11-18 | Aldeyra Therapeutics, Inc. | Pharmaceutical formulations and uses thereof |
| BR112023025221A2 (pt) | 2021-06-02 | 2024-02-27 | Astellas Pharma Inc | Métodos de uso de compostos agonistas de ppar e composições farmacêuticas dos mesmos |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
| WO2025207099A1 (en) * | 2024-03-28 | 2025-10-02 | Astellas Pharma Inc. | Ppar-delta inhibitors for preventing post-operative atrial fibrillation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7396850B2 (en) | 2003-01-06 | 2008-07-08 | Eli Lilly And Company | Pyrazole derivative as PPAR modulator |
| EP1671633A1 (en) * | 2004-12-17 | 2006-06-21 | Sanofi-Aventis Deutschland GmbH | Use of PPAR agonists for the treatment of congestive heart failure |
| AU2006210503B2 (en) * | 2005-02-03 | 2009-09-03 | Irm Llc | Compounds and compositions as PPAR modulators |
| CN101296892A (zh) * | 2005-09-07 | 2008-10-29 | 普莱希科公司 | Ppar活性化合物 |
| DE102006023336A1 (de) * | 2006-05-18 | 2007-11-22 | Merck Patent Gmbh | 1,5-Diphenyl-pyrazole II |
| FR2940289B1 (fr) * | 2008-12-23 | 2014-09-12 | Biopharmed | Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas |
| CN102727489A (zh) * | 2012-07-18 | 2012-10-17 | 西南大学 | 5-芳(杂环)亚甲基噻唑烷-2，4-二酮在制备ppar激动剂中的应用 |
| US20170305894A1 (en) * | 2014-10-08 | 2017-10-26 | Mitobridge, Inc. | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| EA037371B1 (ru) | 2015-10-07 | 2021-03-19 | Митобридж, Инк. | Агонисты ppar, соединения, фармацевтические композиции и способы их применения |
| US11358954B2 (en) | 2016-04-13 | 2022-06-14 | Mitobridge, Inc. | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| ES2859487T3 (es) | 2016-10-05 | 2021-10-04 | Mitobridge Inc | Métodos para tratar las lesiones renales agudas |
| ES2887008T3 (es) | 2016-10-05 | 2021-12-21 | Mitobridge Inc | Formas cristalinas y de sal de compuestos agonistas del PPAR |
-
2017
- 2017-10-05 ES ES17787774T patent/ES2887008T3/es active Active
- 2017-10-05 PT PT177877743T patent/PT3523283T/pt unknown
- 2017-10-05 HU HUE17787774A patent/HUE055678T2/hu unknown
- 2017-10-05 AU AU2017340763A patent/AU2017340763B2/en active Active
- 2017-10-05 CA CA3036587A patent/CA3036587A1/en active Pending
- 2017-10-05 DK DK17787774.3T patent/DK3523283T3/da active
- 2017-10-05 HR HRP20211341TT patent/HRP20211341T1/hr unknown
- 2017-10-05 WO PCT/US2017/055403 patent/WO2018067860A1/en not_active Ceased
- 2017-10-05 KR KR1020197012668A patent/KR20190057129A/ko not_active Ceased
- 2017-10-05 UA UAA201903678A patent/UA124770C2/uk unknown
- 2017-10-05 SG SG11201901995TA patent/SG11201901995TA/en unknown
- 2017-10-05 PL PL17787774T patent/PL3523283T3/pl unknown
- 2017-10-05 MY MYPI2019001560A patent/MY202008A/en unknown
- 2017-10-05 US US16/334,746 patent/US10927094B2/en active Active
- 2017-10-05 RS RS20211042A patent/RS62245B1/sr unknown
- 2017-10-05 JO JOP/2019/0039A patent/JOP20190039B1/ar active
- 2017-10-05 EP EP17787774.3A patent/EP3523283B1/en active Active
- 2017-10-05 SI SI201730879T patent/SI3523283T1/sl unknown
- 2017-10-05 IL IL265730A patent/IL265730B/en unknown
- 2017-10-05 JP JP2019518286A patent/JP7017563B2/ja active Active
- 2017-10-05 TW TW106134298A patent/TWI769182B/zh active
- 2017-10-05 LT LTEPPCT/US2017/055403T patent/LT3523283T/lt unknown
- 2017-10-05 CN CN201780062034.5A patent/CN109843857B/zh active Active
- 2017-10-05 MX MX2019003945A patent/MX385973B/es unknown
- 2017-10-05 MA MA046460A patent/MA46460A/fr unknown
- 2017-10-05 RU RU2019110736A patent/RU2759724C2/ru active
-
2019
- 2019-03-20 ZA ZA2019/01744A patent/ZA201901744B/en unknown
- 2019-03-29 CO CONC2019/0003162A patent/CO2019003162A2/es unknown
- 2019-04-03 PH PH12019500727A patent/PH12019500727A1/en unknown
-
2021
- 2021-02-19 US US17/179,604 patent/US11530192B2/en active Active
- 2021-08-31 CY CY20211100775T patent/CY1124655T1/el unknown
-
2022
- 2022-12-16 US US18/082,847 patent/US11912681B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL265730A (en) | Crystalline forms and salts of ppar agonist compounds | |
| IL254351A0 (en) | An acid addition salt of a trk inhibitory compound | |
| IL247143B (en) | A new use of agonistic compounds for the sigma-1 receptor | |
| SI3380554T2 (sl) | Kristalne oblike per-kloro-gama-ciklodekstrinov | |
| PL3560925T3 (pl) | Nowy związek i jego dopuszczalna farmaceutycznie sól | |
| PT3113773T (pt) | Formas cristalinas do grapiprant | |
| IL266003A (en) | Salts of indazole derivatives and their crystals | |
| SI3529236T1 (sl) | Kristalinične oblike eravaciklina | |
| SG10202101979TA (en) | Crystalline forms of c21h22ci2n4o2 | |
| PL3532457T3 (pl) | Postacie krystaliczne hydroksynorketaminy | |
| IL253479A0 (en) | Crystalline forms of efinconazole | |
| IL246835A0 (en) | Improved process for the preparation of trazodone and its hydrochloride salt | |
| ZA201607107B (en) | Salts and polymorphs of a substituted imidazopyridinyl-aminopyridine compound | |
| IL274758A (en) | Crystalline forms of praquinostat | |
| SG11202105355XA (en) | Crystalline salts of corydalmine | |
| SG11202009262VA (en) | Salts of compounds and crystals thereof | |
| IL270937A (en) | Crystalline forms of saltalicib | |
| ZA201901155B (en) | Salt and crystal of diaza-benzofluorane compound | |
| GB201621771D0 (en) | New salts of compounds and uses thereof | |
| HUP1600613A2 (en) | Crystalline forms of sacubitril hemicalcium salt | |
| GB201621528D0 (en) | Use of trpv1 agonist | |
| IL252162A0 (en) | Crystal forms of poly(adenosine diphosphate) ribose polymerase inhibitors |